


PRODUCT INFORMATION



Nitecapone

Item No. 18656

CAS Registry No.: 116313-94-1
Formal Name: 3-[(3,4-dihydroxy-5-nitrophenyl)methylene]-2,4-pentanedione
Synonym: OR-462
MF: C₁₂H₁₁NO₆
FW: 265.2
Purity: ≥98%
UV/Vis.: λ_{max}: 225, 301 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nitecapone is supplied as a crystalline solid. A stock solution may be made by dissolving the nitecapone in the solvent of choice. Nitecapone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of nitecapone in ethanol is approximately 5 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Nitecapone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, nitecapone should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Nitecapone has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Nitecapone is a reversible inhibitor of S-catechol-O-methyltransferase (S-COMT; IC₅₀ = 300 nM in rat liver).¹ It is selective for S-COMT over tyrosine hydroxylase, dopamine-β-hydroxylase, DOPA decarboxylase, monoamine oxidase A (MAO-A), and MAO-B (IC₅₀s = >1 μM for all). *In vivo*, nitecapone inhibits liver, duodenal, and brain S-COMT (ID₅₀s = 5, 5, and 25 mg/kg, respectively). Nitecapone (3–30 mg/kg) reduces 3-O-methyl-DOPA (3-OMD) formation and increases serum and brain L-DOPA, dopamine, and DOPAC levels when administered in combination with L-DOPA (Item No. 13248) and carbidopa (Item No. 23783). Nitecapone (30 mg/kg) reduces mechanical and cold allodynia in a rat model of spinal nerve ligation-induced neuropathy.²

References

1. Männistö, P.T. and Kaakkola, S. *Pharmacol. Rev.* **51**(4), 593-628 (1999).
2. Kambur, O., Männistö, P.T., Pusa, A.M., et al. *Eur. J. Pain.* **15**(7), 732-740 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/28/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM